Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors

1. A compound having the formula:

or a pharmaceutically acceptable salt thereof,

wherein:

B is C 3 -C 7 cycloalkyl, which may be optionally substituted with one or more groups, each independently selected from R 6 ;

X is C 1 -C 3 alkylene;

Y is —CH 2 —, —CH(R 6 )— or —N(R 3 )—;

R is H or benzyl;

R 1 is selected from H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, —(C 1 -C 4 alkylene)-O—(C 1 -C 6 alkyl), —(C 1 -C 4 alkylene)-S—(C 1 -C 6 alkyl), —(C 1 -C 4 alkylene)-SO 2 —(C 1 -C 6 alkyl), —(C 1 -C 4 alkylene)-N—(C 1 -C 6 alkyl) 2 , —(C 1 -C 6 alkylene) m -Z—(C 1 -C 3 alkylene) m -R 11 , C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, phenyl, 3 to 8-membered monocyclic heterocycloalkyl and 5 or 6-membered monocyclic heteroaryl;

R 2 represents up to 3 optional substitutents, each independently selected from halo, C 1 -C 6 alkyl, —O—(C 1 -C 6 alkyl) and C 1 -C 6 haloalkyl;

R 3 is selected from H, C 1 -C 6 alkyl, —SO 2 R 4 , —C(O)R 4 , —(C 1 -C 6 alkylene) p -C(O)N(R 5 ) 2 , —(C 2 -C 4 alkylene)-O—(C 1 -C 6 alkyl), —(C 2 -C 4 alkylene)-S—(C 1 -C 6 alkyl), —(C 2 -C 4 alkylene)-SO 2 —(C 1 -C 6 alkyl), —(C 2 -C 4 alkylene)-N—(C 1 -C 6 alkyl) 2 , —(C 1 -C 6 alkylene) m -Z—(C 1 -C 3 alkylene) m -R 11 , C 3 -C 7 cycloalkyl, phenyl, 4 to 8-membered monocyclic heterocycloalkyl or 6-membered monocyclic heteroaryl and 8 to 10-membered bicyclic heteroaryl;

each occurrence of R 4 is independently selected from H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 7 cycloalkyl, phenyl, 3 to 8-membered monocyclic heterocycloalkyl, 5 or 6-membered monocyclic heteroaryl and 8 to 10-membered bicyclic heteroaryl, wherein said C 3 -C 7 cycloalkyl group, said phenyl group, said 3 to 8-membered monocyclic heterocycloalkyl group, said 5 or 6-membered monocyclic heteroaryl group and said 8 to 10-membered bicyclic heteroaryl group may be optionally substituted with one or more groups, each independently selected from R 6 ;

each occurrence of R 5 is independently selected from H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, —(C 1 -C 6 alkylene)-N(R 7 ) 2 , C 1 -C 6 haloalkyl, —C(O)O(C 1 -C 6 alkyl), —(C 1 -C 6 alkylene) m -Z—(C 1 -C 3 alkylene) m -R 11 , —(C 1 -C 6 alkylene) p -R 8 and —(C 1 -C 6 alkylene)-O—(C 1 -C 6 alkyl);

each occurrence of R 6 is independently selected from halo, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —(C 1 -C 6 alkylene) m -Z—(C 1 -C 3 alkylene) m -R 11 , —N(R 20 ) 2 , 3 to 8-membered monocyclic heterocycloalkyl, 6 to 10-membered bicyclic heterocycloalkyl, —O—(C 1 -C 6 alkyl), —O—(C 6 -C 10 aryl), —O—(C 1 -C 6 alkylene)-O—(C 1 -C 6 alkyl), —O—(C 1 -C 6 haloalkyl), —O—(C 1 -C 6 alkylene)-O—(C 1 -C 6 alkylene)-O—(C 1 -C 6 alkyl), —S(O) 2 (C 1 -C 6 alkyl), —NHS(O) 2 —(C 1 -C 6 alkyl), —S(O) 2 NH—(C 1 -C 6 alkyl), —OC(O)—(C 1 -C 6 haloalkyl), —(C 1 -C 6 alkylene) p -C(O)O—(C 1 -C 6 alkyl), —(C 1 -C 6 alkylene) p -C(O)—(C 1 -C 6 alkyl), —(C 1 -C 6 alkylene) p -C(O)N(R 7 ) 2 , C 1 -C 6 hydroxyalkyl, —P(O)(OR 9 ) 2 , and —CN;

each occurrence of R 7 is independently selected from H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, C 1 -C 6 haloalkyl, —C(O)O(C 1 -C 6 alkyl), —(C 1 -C 6 alkylene) m -Z—(C 1 -C 3 alkylene) m -R 11 , —(C 1 -C 6 alkylene) p -R 8 and —(C 1 -C 6 alkylene)-O—(C 1 -C 6 alkyl);

each occurrence of R 8 is independently selected from H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, 5 or 6-membered monocyclic heteroaryl and 3 to 8-membered monocyclic heterocycloalkyl;

each occurrence of R 9 is independently selected from H, C 1 -C 6 alkyl and —(C 1 -C 6 alkylene) m -Z—(C 1 -C 3 alkylene) m -R 11 ;

R 10 is selected from H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl and —(C 1 -C 4 alkylene)-O—(C 1 -C 6 alkyl);

each occurrence of R 11 is independently selected from —P(O)(—OR 18 ) 2 ,

each occurrence of R 12 is independently selected from H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, phenyl or benzyl, wherein said C 1 -C 6 alkyl may be optionally substituted with a group selected from halo, —OR 16 , —SR 16 , guanidino, —N(R 16 ) 2 , —C(O)OR 16 , —C(O)N(R 16 ) 2 , —NHC(O)R 16 , 5- or 6-membered monocyclic heteroaryl and 9- or 10-membered bicyclic heteroaryl, and wherein said phenyl group and said benzyl group may be optionally substituted with up to 2 groups, each independently selected from C 1 -C 6 alkyl, halo and —OR 16 ;

each occurrence of R 13 is independently selected from H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, phenyl or benzyl, wherein said C 1 -C 6 alkyl may be optionally substituted with a group selected from halo, —OR 16 , —SR 16 , guanidino, —N(R 16 ) 2 , —C(O)OR 16 , —C(O)N(R 16 ) 2 , —NHC(O)R 16 , 5- or 6-membered monocyclic heteroaryl and 9- or 10-membered bicyclic heteroaryl, and wherein said phenyl group and said benzyl group may be optionally substituted with up to 2 groups, each independently selected from C 1 -C 6 alkyl, halo and —OR 16 ;

each occurrence of R 14 is independently selected from H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, —(C 1 -C 3 alkylene) m -(C 3 -C 7 cycloalkyl), —(C 1 -C 3 alkylene) m -(C 6 -C 10 aryl) or —(C 1 -C 3 alkylene) m -adamantyl, wherein said C 1 -C 20 alkyl group, said C 2 -C 20 alkenyl group, said C 6 -C 10 aryl group and said adamantyl group may be optionally substituted with up to three groups, each independently selected from halo, —OR 16 , —C(O)OR 16 , CN, NO 2 , C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 3 -C 7 cycloalkyl, C 6 -C 10 aryl, 5- or 6-membered monocyclic heteroaryl, 9- or 10-membered bicyclic heteroaryl, —N(R 16 ) 2 , —C(O)N(R 16 ) 2 —SR 16 , —S(O)R 16 , —S(O) 2 R 16 , —S(O) 2 N(R 16 ) 2 , —NHC(O)R 16 , —NHC(O)OR 16 and —NHC(O)N(R 16 ) 2 ;

R 15 is H, C 6 -C 10 aryl, 5- or 6-membered monocyclic heteroaryl or 9- or 10-membered bicyclic heteroaryl, wherein said C 6 -C 10 aryl group, said 5- or 6-membered monocyclic heteroaryl group and said 9- or 10-membered bicyclic heteroaryl group may be optionally substituted with R 17 ;

each occurrence of R 16 is independently H, C 1 -C 10 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, —(C 1 -C 3 alkylene) m -(C 3 -C 7 cycloalkyl), —(C 1 -C 3 alkylene) m -(C 6 -C 10 aryl), —(C 1 -C 3 alkylene) m -(4 to 7-membered heterocycloalkyl), —(C 1 -C 3 alkylene) m -(5- or 6-membered monocyclic heteroaryl) or —(C 1 -C 3 alkylene) m -(9- or 10-membered bicyclic heteroaryl), wherein said C 3 -C 7 cycloalkyl group, said C 6 -C 10 aryl group, said 4 to 7-membered heterocycloalkyl group, said -5- or 6-membered monocyclic heteroaryl group or said 9- or 10-membered bicyclic heteroaryl group may be optionally substituted with R 17 ;

R 17 represents from one to five substituent groups, each independently selected from C 1 -C 6 alkyl, halo, —OR 19 , —SR 19 , C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, —O—(C 1 -C 6 haloalkyl), —CN, —NO 2 , —N(R 19 ) 2 , —C(O)OR 19 , —C(O)N(R 19 ) 2 and —NHC(O)R 19 ;

each occurrence of R 18 is independently selected from H, C 1 -C 6 alkyl, C 6 -C 10 aryl, —(C 1 -C 6 alkylene)-O—(C 1 -C 20 alkyl), —(C 1 -C 6 alkylene)-O—C(O)—R 16 , and —(C 1 -C 6 alkylene)-O—C(O)—O—R 16 ;

each occurrence of R 19 is independently H, C 1 -C 10 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, —(C 1 -C 3 alkylene) m -(C 3 -C 7 cycloalkyl), —(C 1 -C 3 alkylene) m -(C 6 -C 10 aryl), —(C 1 -C 3 alkylene) m -(4 to 7-membered heterocycloalkyl), —(C 1 -C 3 alkylene) m -(5- or 6-membered monocyclic heteroaryl) or —(C 1 -C 3 alkylene) m -(9- or 10-membered bicyclic heteroaryl);

each occurrence of R 20 is independently selected from H, C 1 -C 6 alkyl and —(C 1 -C 6 alkylene) m -Z—(C 1 -C 3 alkylene) m -R 11 ;

each occurrence of Z is independently selected from a bond, —O— or —N(R 9 )—;

each occurrence of m is independently 0 or 1; and

each occurrence of p is independently 0 or 1,

such that at least one occurrence of R 11 must be present in the compound of formula (I).

2. The compound of claim 1 , wherein X is —CH 2 —, or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein R 10 is H—, or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein B is cyclopentyl or cyclohexyl, which is optionally substituted with —(C 1 -C 6 alkylene) m -R 11 —, or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , having the formula (Ia):

or a pharmaceutically acceptable salt thereof,

wherein:

B is cyclopentyl or cyclohexyl, optionally substituted with R 6 ;

R 1 is C 1 -C 6 alkyl or —(C 1 -C 6 alkylene)-R 11 ;

R 2 represents up to 2 optional substituents, each independently selected from halo; and

R 3 is C 1 -C 6 alkyl or —(C 1 -C 6 alkylene)-R 11 ;

R 6 is —(C 1 -C 6 alkylene) m -R 11 ;

each occurrence of R 11 is independently selected from —P(O)(—OR 18 ) 2 and:

R 12 is independently selected from H and C 1 -C 6 alkyl;

R 13 is independently selected from H and C 1 -C 6 alkyl;

R 14 is C 1 -C 6 alkyl;

R 15 is C 6 -C 10 aryl;

each occurrence of R 18 is independently selected from H and C 1 -C 6 alkyl; and

m is 0 or 1,

such that at least one occurrence of R 11 must be present in the compound of formula (I).

6. The compound of claim 1 , wherein R 2 represents up to 2 optional substituents, each independently selected from halo, or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein B is substituted with —(C 1 -C 6 alkylene) m -R 11 , or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , wherein R 3 is —(C 1 -C 6 alkylene)-R 11 , or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , wherein R 1 is methyl or ethyl, or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 , wherein R 2 represents two fluoro groups, in the ortho and para positions, or a pharmaceutically acceptable salt thereof.

11. A compound selected from

or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

13. A method for the inhibition of HIV integrase in a subject in need thereof which comprises administering to the subject an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

14. A method for the treatment of infection by HIV or for the treatment, prophylaxis, or delay in the onset or progression of AIDS in a subject in need thereof, which comprises administering to the subject an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

15. The pharmaceutical composition of claim 12 , further comprising one or more additional therapeutic agents selected from raltegravir, lamivudine, abacavir, ritonavir, dolutegravir, arunavir, atazanavir, emtricitabine, tenofovir, elvitegravir, rilpivirine and lopinavir.

16. The method of claim 14 , further comprising administering to the subject one or more additional therapeutic agents selected from raltegravir, abacavir, lamivudine, ritonavir and lopinavir, wherein the amounts administered of the compounds are together effective to treat infection by HIV or to treat, prevent or delay the onset or progression of AIDS.